Sun Pharmaceutical Industries Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹15,521Cr
- +13.5% YoY
- +7.2% QoQ
- Net profit
- ₹3,381Cr
- +16.1% YoY
- +8.2% QoQ
- Margin
- 32%
- +3 pp YoY
- +1 pp QoQ
Guidance rank: #86 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals. EBITDA and earnings showed a 13-14% CAGR from FY23 to FY25, indicating strong growth momentum prior to FY26 nine months.
From Sun Pharmaceutical Industries Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals.
- Emerging markets showed buoyant growth with 13% constant currency growth, driven by both generics and innovative products, and broad-based growth in key countries like Romania, South Africa, and Brazil.
- Global innovative medicines sales grew 14.3% YoY; specialty business expected to continue doing well, but difficult to comment on quarter-to-quarter basis.
- US business saw marginal growth (0.6%) with some generic sales decline; recovery expected as manufacturing compliance improves enabling new product launches.
- Volume growth in India was strong at 6.3%, outperforming the overall market (IPM at 1.2%).
2 more points from Sun Pharmaceutical Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sun Pharmaceutical Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sun Pharma is investing in building an R&D pipeline for both global generics and innovative medicines.
- Consolidated R&D investment for Q3 FY26 was Rs. 8,928 million (5.8% of sales), with innovative R&D accounting for 30.5% of total R&D spend.
- The company has initiated global Phase-II trials of GL0034 (type-2 diabetes) and filed sBLA for Ilumya with the US FDA.
- Incremental spend of approximately $100 million is planned on new launches like LEQSELVI and UNLOXCYT; this spend will become part of core operating expenses.
2 more points from Sun Pharmaceutical Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharmaceutical Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sun Pharmaceutical Industries Ltd said on order book & pipeline — free account, 30 seconds.
Sun Pharmaceutical Industries Ltd — Quarterly revenue & net profit
Sun Pharmaceutical Industries Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 15,521 | 13,675 | +13.5% | 14,478 | +7.2% |
| Operating profit (EBITDA) | 4,948 | 4,009 | +23.4% | 4,527 | +9.3% |
| Operating margin | 32% | 29% | +3 pp | 31% | +1 pp |
| Profit before tax | 4,227 | 3,476 | +21.6% | 4,168 | +1.4% |
| Net profit (PAT) | 3,381 | 2,913 | +16.1% | 3,125 | +8.2% |
| EPS (₹) | 14.04 | 12.10 | +16% | 13.00 | +8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹16.2K Cr, net profit ₹2.0K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharmaceutical Industries's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharmaceutical Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharmaceutical Industries Ltd Q3 FY26 results?
India business expects growth improvement with the upcoming launch of Semaglutide (SEMA) in chronic weight management and type 2 diabetes; the company is preparing for a day-one generic launch and has already received regulatory approvals. EBITDA and earnings showed a 13-14% CAGR from FY23 to FY25, indicating strong growth momentum prior to FY26 nine months.
What is Sun Pharmaceutical Industries Ltd share price analysis?
Sun Pharmaceutical Industries Ltd currently shows a neutral. The stock trades at a P/E of 36.7 with a market cap of ₹463,072 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharmaceutical Industries Ltd planning capital expenditure?
Sun Pharma is investing in building an R&D pipeline for both global generics and innovative medicines.
Keep Sun Pharmaceutical Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
